-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IugI4lfp/r5PiRfsT/C/MIKM9jAB120SxlteSIulzAfQQ7r7kKjpuzEiFtGmkToT WLeNcj5hZV2pR7CrkEVamw== 0000909518-03-000313.txt : 20030520 0000909518-03-000313.hdr.sgml : 20030520 20030520103650 ACCESSION NUMBER: 0000909518-03-000313 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030430 FILED AS OF DATE: 20030520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARO PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000906338 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22286 FILM NUMBER: 03711492 BUSINESS ADDRESS: STREET 1: 14 HAKTOR ST CITY: HAIFA BAY STATE: L3 ZIP: 26110 MAIL ADDRESS: STREET 1: FIVE SKYLINE DR CITY: HAWTHORNE STATE: NY ZIP: 10532 FORMER COMPANY: FORMER CONFORMED NAME: TARO VIT INDUSTRIES LTD /ISRAEL/ DATE OF NAME CHANGE: 19930601 6-K 1 jd5-20_6k.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2003 Commission File Number: 0-22286 Taro Pharmaceutical Industries Ltd. - -------------------------------------------------------------------------------- (Translation of registrant's name into English) Italy House, Euro Park, Yakum 60972, Israel - -------------------------------------------------------------------------------- (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F |X| Form 40-F |_| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes |_| No |X| The following is included in this Report on Form 6-K: 1. English summary of the registrant's filings in Hebrew with the Israeli Registrar of Companies during April 2003. 2 SUMMARY OF FILINGS ------------------ During April 2003, Taro Pharmaceutical Industries Ltd. (the "Registrant") filed with the Israeli Registrar of Companies reports of the following issuances of ordinary shares of the Registrant (par value NIS 0.0001 per ordinary share):
- ------------------------------------------------------ ---------------------- ------------------ ------------------------------- NUMBER OF SHARES PRICE PER SHARE (NIS) SHAREHOLDER DATE - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Marton Klein 2/27/2003 25 12.05 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Dick Guest 3/6/2003 1,250 32.14 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Adrian Rebello 3/6/2003 74 11.97 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Barry Fishman 3/13/2003 30,000 24.39 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Barry Fishman 3/13/2003 1,000 61.78 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Silkander Remtulla 3/17/2003 25 11.99 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Susi Antoniuk 3/19/2003 25 11.99 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Walter Jenkins 3/25/2003 1,000 14.25 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Hermona Hills 3/26/2003 4,500 15.89 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Tim Conliffe 3/27/2003 25 11.70 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Bogumila Lysenko 4/4/2003 50 11.61 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Dhaniram Bishundeo 4/7/2003 25 11.56 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Alok Sadana 4/7/2003 25 11.56 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Karl Nursch 4/7/2003 100 11.33 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Karl Nursch 4/7/2003 100 11.56 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Hermona Hills 3/26/2003 4,500 15.70 - ------------------------------------------------------ ---------------------- ------------------ ------------------------------- Robert Mauro 4/9/2003 500 11.51 - ------------------------------------------------------ ---------------------- ------------------ -------------------------------
3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Taro Pharmaceutical Industries Ltd. Date: May 19, 2003 By:/s/ Kevin Connelly ---------------------------------- Kevin Connelly Senior Vice President and Chief Financial Officer 4 -----END PRIVACY-ENHANCED MESSAGE-----